ArticleInternational journal of molecular sciences2019
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Label-Free SERS Analysis of Glioma Cells to Detect Drug Resistance Using Metabolic Phenylalanine Level.ACS measurement science au · 2026Article
- Cellular Senescence Triggered by Food and Environmental Genotoxins.International journal of molecular sciences · 2026Review
- Review
- The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma.Exploration of targeted anti-tumor therapy · 2026Review
- Apoptotic and senolytic effects of hERG/Eag1 channel blockers in combination with temozolomide in human glioblastoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy.ACS applied materials & interfaces · 2025Article
- Senescence- and Immunity-Related Changes in the Central Nervous System: A Comprehensive Review.Aging and disease · 2024Review
- Review
- Temozolomide and flavonoids against glioma: from absorption and metabolism to exosomal delivery.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications.Journal of clinical medicine · 2023Review
- HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma.CNS neuroscience & therapeutics · 2023Article
- Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.PLoS computational biology · 2023Article
- Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG.Molecular oncology · 2023Article
- Article
- Temozolomide and chloroquine co-loaded mesoporous silica nanoparticles are effective against glioma.Heliyon · 2023Article
- Non-canonical NLRC4 inflammasomes in astrocytes contribute to glioma malignancy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Review
- SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.Bioengineered · 2022Article
- Article
- Temozolomide - Just a Radiosensitizer?Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Temozolomide (TMZ) is an alkylating agent used in the treatment of high-grade malignant glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer. The drug induces a dozen DNA methylation adducts, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.